| Feb 3, 2026 | Skyryse | $300.0M Series C | Autopilot | ArrowMark Partners, Atreides Management, BAM Elevate, Baron Capital Group, Durable Capital Partners, Fidelity Management & Research Company, Positive SUM, Qatar Investment Authority, Rokos Capital Management |
| Jan 12, 2026 | Mirador Therapeutics | $250.0M Series B | — | Adage Capital Management, ARCH Venture Partners, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, TCGX, T. Rowe Price Associates, Venrock |
| Nov 18, 2025 | Ursa Major | $150.0M Debt / Series E | Lior Susan | Gilman Louie, Principia, XN |
| Sep 6, 2024 | OrsoBio | $67.0M Series B | Evan Rachlin, Woodline Partners | — |
| Apr 3, 2024 | Obsidian Therapeutics | $160.5M Series C | Irina Margine, Ph.d. | Atlas Venture, Bristol Myers Squibb, Deep Track Capital, Foresite Capital, Janus Henderson Investors, Logos Capital, RAY Camahort, Paradigm BioCapital, RA Capital Management, RTW Investments, Samsara BioCapital, Surveyor Capital, TCGX, T. Rowe Price Associates |
| Apr 1, 2024 | Endeavor BioMedicines | $130.0M Series C | Ayurmaya, Karan Takhar | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, Abrdn, Ally Bridge Group, Avidity Partners, Eckuity Capital, Fidelity Management & Research Company, Invus, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch BIO, SymBiosis, T. Rowe Price Associates, Velosity Capital |
| Mar 1, 2024 | Mirador Therapeutics | $400.0M Series A | ARCH Venture Partners | Cambridge Innovation Capital, HealthCap, Mubadala, Alexandria Venture Investments, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Invus, Logos Capital, OrbiMed, Point72, RTW Investments, Sanofi Ventures, TCGX, Venrock |
| Jan 1, 2024 | Build A Rocket Boy | $110.0M Series D | Julia Wittlin | Alumni Ventures, Cultivation Capital, Endeavor, Galaxy Digital, Gtam Partners, NetEase Games |
| Dec 1, 2023 | Odyssey Therapeutics | $100.0M Series C | Lorence KIM | OrbiMed, SR ONE, Third Rock Ventures, AB Magnitude Ventures Group, Alexandria Venture Investments, Blackmars Capital, Catalio Capital, Colt Ventures, Creacion Ventures, CU Healthcare Innovation Fund, Fidelity Management & Research Company, Foresite Capital, General Catalyst, Global Bioaccess Fund, HBM Healthcare Investments, KB Investment, Racing Beach Ventures, T. Rowe Price Associates, Walleye Capital |
| Jul 1, 2023 | Septerna | $150.0M Series B | Jake Simson | Samsara BioCapital, Sanofi Ventures, Third Rock Ventures, BVF Partners, Casdin Capital, Catalio Capital, Deep Track Capital, Driehaus Capital Management, Goldman Sachs, Invus, Logos Capital, Mirae Asset, Solus Capital, Vertex Ventures HC |
| May 1, 2023 | ElevateBio | $400.0M Series D | Ayurmaya, Matrix Capital Management | MPM Capital, RA Capital, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Management & Research Company, Khalil Barrage, LEE Family Office, Karina Thorn, R&D Partner, Redmile Group, Samsara BioCapital, Softbank, Surveyor Capital, Vertex Ventures |
| Oct 1, 2022 | Odyssey Therapeutics | $170.0M Series B | General Catalyst | Atlas Venture, EQT Life Sciences, F7 Ventures, Foresite Capital, OrbiMed, Pivotal BioVenture Partners, Soffinova Partners, SR ONE, Alexandria Venture Investments, Catalio Capital, Colt Ventures, Creacion Ventures, Fidelity Management & Research Company, GreatPoint Ventures, HBM Healthcare Investments, Leerink Partners, Logos Capital, T. Rowe Price Associates, Walleye Capital |
| Dec 1, 2021 | Odyssey Therapeutics | $220.0M Series A | OrbiMed, SR ONE | Atlas Venture, EQT Life Sciences, Foresite Capital, Pivotal BioVenture Partners, Soffinova Partners, Colt Ventures, Creacion Ventures, HBM Healthcare Investments, Logos Capital |
| Nov 9, 2021 | Arbor Biotechnologies | $215.0M Series B | Frank YU, Chen YU, Temasek | ARCH Venture Partners, ArrowMark Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, ONO Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, TAO Capital Partners, Tekla Capital Management, T. Rowe Price Associates, Vertex |
| Oct 1, 2021 | Structure Therapeutics | $100.0M Series B | Mark Nathan Lampert | Qiming Venture Partners, Casdin Capital, Cormorant Asset Management, Eight Roads Ventures, F Prime Capital, Hongshan Capital Group (Sequoia Capital China), Janus Henderson Investors, Lilly Asia Ventures, Monashee Investment Management, Sage Partners, Schr"dinger, Stork Capital, Surveyor Capital, Chen YU, Terra Magnum Capital Partners, TF Capital, WuXi AppTec |
| Oct 1, 2021 | Cedilla Therapeutics | $25.0M Series B | — | RED Tree Venture Capital, Janus Henderson Investors, Logos Capital, Jake Simson, Third Rock Ventures |
| Sep 15, 2021 | SmartNews | $230.0M Series F | — | ACA Investments, Green Co Invest Investment, JIC Venture Growth Investments, Princeville Capital, SMBC Venture Capital, Yamauchi No.10 Family Office |
| Sep 1, 2021 | LEXEO Therapeutics | $100.0M Series B | Daniel Saul Sundheim, JOY Ghosh | Omega Funds, Alexandria Venture Investments, CAM Capital, Gray's Creek Capital Partners, Invus, Janus Henderson Investors, Laurion Capital Management, Longitude Capital, Lundbeckfond Ventures, PBM Capital, Verition Fund Management |
| Jul 20, 2021 | Amylyx Pharmaceuticals | $135.0M Series C | Viking Global Investors | Belinda Termeer, 683 Capital Management, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management |
| Jul 14, 2021 | Kriya Therapeutics | $100.0M Series B | JIM Momtazee | Alumni Ventures, Amplo, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, Hongkou, JDRF, Narya Capital, QVT, Transhuman Capital |
| May 1, 2021 | Affinia Therapeutics | $110.0M Series B | Caroline Stout, Farallon Capital Management | Atlas Venture, F Prime Capital, ED Mathers, NEW Enterprise Associates, Avidity Partners, Casdin Capital, F Prime Capital, GV, Lonza, Mass General Brigham Ventures, Octagon Capital, Perceptive Advisors, RA Capital Management, TCGX |
| Apr 1, 2021 | Patreon | $160.0M Series F | Tiger Global Management | DFJ, Insight Partners, London Venture Partners, SciFi VC, Sequoia Capital, David LAU KEE, Paul Heydon, Lone Pine Capital, NEW Enterprise Associates, Wellington Management |
| Mar 4, 2021 | atai Life Sciences | $157.0M Series D | Christian Angermayer, Apeiron Investment Group, Thiel Capital | Catalio Capital, Falcon Edge Capital, Fearless Ventures, Highline Capital Management, Pura Vida Investments, Michael Auerbach |
| Feb 1, 2021 | Vividion Therapeutics | $140.0M Series C | Aaron Davis, Graham Walmsley | ARCH Venture Partners, Cure Ventures, Earlybird Venture Capital, Versant Ventures, Vivo Capital, Avoro Capital Advisors, BlackRock, BVF Partners, Casdin Capital, Driehaus Capital Management, Mubadala Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates |
| Jan 1, 2021 | LEXEO Therapeutics | $85.0M Series A | Omega Funds, Sandip Agarwala | Alexandria Venture Investments, Alzheimer's Drug Discovery Foundation, Invus, Janus Henderson Investors, Mette Kirstine Agger, PBM Capital |
